Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Leuk Lymphoma. 2012 Jul 9;54(2):408–410. doi: 10.3109/10428194.2012.701009

Figure 1.

Figure 1

(A) Fold changes in 2-hydroxyglutarate in patients with AML with IDH mutations. (B–D) Fold changes in 2-hydroxyglutarate, 5-hydroxymethylcytosine and 5-methylcytosine in patient B (IDHMUT TET2WT) after achieving a post-cycle 1 complete remission (B) and at relapse (C), and in patient C (IDHMUT TETMUT) after achieving a post-cycle 1 complete remission (D).